



Supplemental Figures



Supplemental Figure 1: T-CEP binding to target antigens was demonstrated by enzyme-linked immunosorbent assay (ELISA). A sandwich ELISA was carried out by coating T-CEP on high-binding wells (4µg/mL) and target antigens added to wells. The binding of recombinant human CD3εδ-Fc (4µg/mL), recombinant human CD28-Fc (4µg/mL), and an Fc-matched control (4µg/mL) was detected using an anti-hlgG-HRP conjugate (n=3, one-way ANOVA with Dunnett's test). **Terms:** rhCD3εδ, recombinant human CD3εδ; rhCD28, recombinant human CD28; **Symbols:** *** P<0.001.



Supplemental Figure 2: The individual expansion profiles of PBMC Donors #4 (left) and #5 (right). For each donor, the number of viable cells were counted in duplicate samples using a hemocytometer following the staining of dead cells with trypan blue for each expansion method tested **(A)** 12-Day expansion using specified stimulation and low level of IL-2. **(B)** CD4⁺ and CD8⁺ T-cell expansions of two donors. The fold expansion was calculated based on the starting number of CD4⁺ and CD8⁺ T-cells. **Terms:** TACs, Tetrameric antibody complexes; i αCD3, Immobilized anti-CD3; s αCD28, Soluble anti-CD28. **Symbols:** □, T-CEP; ○, TACs; ◇, i αCD3 + s αCD28; △, i αCD3.